3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:百万円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 10,603 | 10,126 |
売掛金 | 15,184 | 16,022 |
有価証券 | 555 | 893 |
商品及び製品 | 15,041 | 14,743 |
仕掛品 | 544 | 416 |
原材料及び貯蔵品 | 11,032 | 14,022 |
その他 | 5,423 | 5,265 |
貸倒引当金 | △94 | △67 |
流動資産合計 | 58,290 | 61,424 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 11,708 | 12,654 |
減価償却累計額 | △6,610 | △6,978 |
建物及び構築物(純額) | 5,097 | 5,676 |
機械装置及び運搬具 | 17,168 | 18,040 |
減価償却累計額 | △15,047 | △15,612 |
機械装置及び運搬具(純額) | 2,121 | 2,428 |
土地 | 4,255 | 4,186 |
建設仮勘定 | 6,508 | 6,078 |
その他 | 3,941 | 4,542 |
減価償却累計額 | △3,258 | △3,667 |
その他(純額) | 683 | 874 |
有形固定資産合計 | 18,667 | 19,244 |
無形固定資産 | | |
のれん | 2,611 | 2,354 |
その他 | 7,602 | 6,514 |
無形固定資産合計 | 10,213 | 8,869 |
投資その他の資産 | | |
投資有価証券 | 12,666 | 17,299 |
繰延税金資産 | 2,312 | 2,254 |
退職給付に係る資産 | - | 111 |
その他 | 2,162 | 2,827 |
貸倒引当金 | △17 | △17 |
投資その他の資産合計 | 17,123 | 22,474 |
固定資産合計 | 46,004 | 50,588 |
資産合計 | 104,295 | 112,012 |
| | (単位:百万円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
負債の部 | | |
流動負債 | | |
買掛金 | 6,411 | 5,288 |
電子記録債務 | 2,735 | 2,270 |
短期借入金 | 2,521 | 1,707 |
1年内返済予定の長期借入金 | 1,940 | 1,562 |
未払金 | 6,194 | 6,446 |
未払法人税等 | 173 | 1,574 |
賞与引当金 | 1,210 | 1,250 |
役員賞与引当金 | 73 | 66 |
その他 | 1,617 | 2,124 |
流動負債合計 | 22,879 | 22,291 |
固定負債 | | |
長期借入金 | 6,441 | 8,165 |
退職給付に係る負債 | 206 | 23 |
その他 | 2,952 | 5,080 |
固定負債合計 | 9,601 | 13,268 |
負債合計 | 32,480 | 35,559 |
純資産の部 | | |
株主資本 | | |
資本金 | 1,197 | 1,197 |
資本剰余金 | - | 31 |
利益剰余金 | 59,545 | 63,352 |
自己株式 | △704 | △658 |
株主資本合計 | 60,039 | 63,923 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 4,853 | 5,646 |
為替換算調整勘定 | - | △292 |
退職給付に係る調整累計額 | 417 | 716 |
その他の包括利益累計額合計 | 5,271 | 6,070 |
非支配株主持分 | 6,504 | 6,459 |
純資産合計 | 71,814 | 76,452 |
負債純資産合計 | 104,295 | 112,012 |
E3579148860あすか製薬ホールディングス株式会社ASKA Pharmaceutical Holdings Co., Ltd.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-04-012026-03-31FY2026-03-312024-04-012025-03-312025-03-311falsefalsefalse488602024-04-012025-03-31jppfs_cor:NonControllingInterestsMember488602024-04-012025-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602024-03-31jppfs_cor:NonControllingInterestsMember488602025-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602026-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember488602025-04-012026-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember488602025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember488602024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember488602025-04-012026-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602026-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602026-03-31jppfs_cor:ShareholdersEquityMember488602026-03-31jppfs_cor:TreasuryStockMember488602026-03-31jppfs_cor:RetainedEarningsMember488602026-03-31jppfs_cor:CapitalSurplusMember488602026-03-31jppfs_cor:CapitalStockMember488602024-03-31jppfs_cor:ShareholdersEquityMember488602024-03-31jppfs_cor:CapitalStockMember488602024-03-31jppfs_cor:CapitalSurplusMember488602024-03-31jppfs_cor:RetainedEarningsMember488602024-03-31jppfs_cor:TreasuryStockMember488602024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602024-04-012025-03-31jppfs_cor:ShareholdersEquityMember488602024-04-012025-03-31jppfs_cor:CapitalStockMember488602024-04-012025-03-31jppfs_cor:CapitalSurplusMember488602024-04-012025-03-31jppfs_cor:RetainedEarningsMember488602024-04-012025-03-31jppfs_cor:TreasuryStockMember488602024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602024-04-012025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602026-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602024-04-012025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602026-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602026-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602026-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602026-03-31jpcrp_cor:ReconcilingItemsMember488602025-04-012026-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602025-04-012026-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602025-04-012026-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602025-04-012026-03-31jpcrp_cor:ReconcilingItemsMember488602025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602025-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602025-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602025-03-31jpcrp_cor:ReconcilingItemsMember488602024-04-012025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602024-04-012025-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602024-04-012025-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602025-04-012026-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember488602026-03-31jppfs_cor:NonControllingInterestsMember488602025-04-012026-03-31jppfs_cor:NonControllingInterestsMember488602025-03-31jppfs_cor:NonControllingInterestsMember488602026-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602025-04-012026-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602025-04-012026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602025-04-012026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602025-04-012026-03-31jppfs_cor:ShareholdersEquityMember488602025-04-012026-03-31jppfs_cor:TreasuryStockMember488602025-04-012026-03-31jppfs_cor:RetainedEarningsMember488602025-04-012026-03-31jppfs_cor:CapitalSurplusMember488602025-04-012026-03-31jppfs_cor:CapitalStockMember488602025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602025-03-31jppfs_cor:ShareholdersEquityMember488602025-03-31jppfs_cor:TreasuryStockMember488602025-03-31jppfs_cor:RetainedEarningsMember488602025-03-31jppfs_cor:CapitalSurplusMember488602025-03-31jppfs_cor:CapitalStockMember488602025-04-012026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602026-05-11488602026-03-31488602025-04-012026-03-31488602025-03-31488602024-04-012025-03-31488602024-03-31xbrli:pureiso4217:JPY